Bente Langdahl
Aarhus University Hospital · Department of Clinical Medicine and Department of Endocrinology and Diabetes, Aarhus University · Department of Endocrinology and Internal medicin, Aarhus University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bente Langdahl as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:01 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07271771 · The Effect of Denosumab on Muscle and Strength and Insulin SensitivityAarhus University Hospital · recruiting · Osteoporosis · principal investigator
- N/ANCT06509776 · Skeletal Maturation and Endocrine Health in Young AdultsHolbaek Sygehus · enrolling by invitation · Osteoporosis, Sarcopenia, Obesity · principal investigator
- Ph4NCT06059222 · The Optimised Use of Romozosumab StudyUniversity of Aarhus · recruiting · Osteoporosis · study director
- Ph4NCT05655013 · Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)Aarhus University Hospital · active not recruiting · Osteoporosis, Postmenopausal · principal investigator
- Ph2NCT01679080 · The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis ImperfectaUniversity of Aarhus · terminated · Osteogenesis Imperfecta · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- F22OC008043RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT06509776
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:01 UTC. The ranking covers the 200 most relevant of 61 PubMed records, and a shared surname and initials can bring in a namesake. All 61 on PubMed
- Romosozumab in postmenopausal women with low bone mineral density.N Engl J Med · 2014974 citationsRCR 34.3
- Fracture risk and zoledronic acid therapy in men with osteoporosis.N Engl J Med · 2012261 citationsRCR 8.7
- A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.J Clin Endocrinol Metab · 2012157 citationsRCR 5.4
- Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.Lancet Diabetes Endocrinol · 2019143 citationsRCR 7.0
- Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.J Bone Miner Res · 2012131 citationsRCR 4.0
- Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial.J Clin Endocrinol Metab · 2014121 citationsRCR 4.5
- Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.J Bone Miner Res · 202094 citationsRCR 5.7
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.J Bone Miner Res · 202192 citationsRCR 6.8
- Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.Osteoporos Int · 200990 citationsRCR 2.8
- A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk.J Clin Endocrinol Metab · 201487 citationsRCR 2.8